||1R01CA219389-01A1 Interpret this number
||H. Lee Moffitt Cancer Ctr & Res Inst
||Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome
Moderate to severe nausea is reported by up to 38% of cancer patients receiving moderately- or highly-
emetogenic chemotherapy despite international antiemetic guidelines. Chemotherapy-induced nausea is
associated with worse quality of life, increased healthcare utilization, and greater costs of care. Previous
research has identified clinical and personal risk factors for nausea (e.g., disease stage, emetogenicity of
chemotherapy, age, sex, history of motion sickness, anxiety, alcohol use), but risk-prediction algorithms based
on these factors demonstrate room for improvement. Recent methodologies for studying the human genome
and microbiome enable us for the first time to develop a more comprehensive understanding of the
pathophysiology of chemotherapy-induced nausea and develop better algorithms. The goal of the current
study is to improve understanding of risk of chemotherapy-induced nausea through integrated examination of
genetic and microbiome variables with well-established clinical and personal risk factors. We will conduct the
first GWAS of chemotherapy-induced nausea, then use pathway analysis to place results into functional
context. Significant variants will be incorporated with clinical and personal factors into a clinical risk prediction
algorithm. This study will also be among the first to examine the association of the gut microbiome with
chemotherapy-induced nausea. Importantly, this study is one of the first to truly integrate biological,
clinical, and patient-reported data to predict risk of treatment toxicity. This groundbreaking study will
be a model for similar efforts in other side effects of chemotherapy such as cognitive impairment, fatigue, and
peripheral neuropathy. Updated risk algorithms from the current study will be made publicly available and
will inform a future randomized trial of risk-based antiemetic cancer care delivery. Positive results will
spur integration of the risk algorithms into the electronic medical record with provider alerts to identify patients
at risk of chemotherapy-induced nausea. Microbiome analyses conducted in the first two years of the study
will provide rapid knowledge about its contributions to chemotherapy-induced nausea. Positive results will
generate additional studies to determine whether microbial manipulation can prevent chemotherapy-induced
nausea. Microbiome data are particularly exciting because they focus on an entirely new mechanism in
chemotherapy-related toxicity. In summary, this rigorous, comprehensive study provides an integrated new
approach to chemotherapy-induced nausea that is expected to significantly advance our understanding of
pathophysiology and risk of this important clinical problem.
Innovations in research and clinical care using patient-generated health data.
, Hoogland A.I.
, Brownstein N.C.
, Barata A.
, Dicker A.P.
, Knoop H.
, Gonzalez B.D.
, Perkins R.
, Rollison D.
, Gilbert S.M.
, et al.
CA: a cancer journal for clinicians, 2020 May; 70(3), p. 182-199.
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
, Zhai W.
, Ahn J.
, Small B.J.
, Ahles T.A.
, Carroll J.E.
, Denduluri N.
, Dilawari A.
, Extermann M.
, Graham D.
, et al.
Cancer, 2020-03-15; 126(6), p. 1183-1192.